

ORCA-3 Second, Confirmatory Phase 3 Topline Results

STUDY OBJECTIVE

Evaluate Efficacy and Safety of
3mg Cytisinicline Dosed 3x Daily

792
PATIENTS

STUDY RESULTS

Primary and Secondary Endpoints Achieved

ORCA-3 demonstrated **statistically significant results** in primary and secondary smoking cessation endpoints for both 6- and 12-week cytisinicline treatment durations compared to placebo.

6X Cytisinicline demonstrated **6x increase in odds of continuous smoking cessation** at 6 months compared to placebo.

Well-tolerated with low rates of adverse events reported.

SMOKING STATISTICS



It is estimated that more than **28 million adults** in the US currently smoke cigarettes.

More than 16 million Americans live with a **smoking-related disease.**




The risk of dying from cigarette smoking has **increased** over the last 50 years in the U.S.

Nearly **12 of every 100**

U.S. adults aged 18 years or older (11.5%) smoked cigarettes in 2021.

11.5%



1 YEAR

480K

Smoking accounts for more than **480,000 deaths every year** in the U.S., including more than 41,000 deaths resulting from secondhand smoke exposure.

Smoking is a significant factor for **cancer, heart disease, stroke, lung diseases, diabetes, COPD, rheumatoid arthritis, and reduced male and female fertility.**